Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Reduced thirst and GI symptoms can raise dehydration risk on GLP-1s
Retatrutide Retatrutide is an investigational weight-loss medication not yet approved by the FDA
CBT-I (Cognitive Behavioral Therapy for Insomnia) Mechanism: Behavioral/psychological intervention with the strongest long-term evidence for chronic insomnia
Food and Drug Administration (FDA), and are not intended to diagnose, treat, cure, or prevent any disease or medical condition
[9] [10] For weight management, GLP-1 medications are typically initiated within specialist weight management services according to NICE criteria
The most common side effects include nausea, vomiting, diarrhoea, decreased appetite, constipation, stomach pain, and indigestion, and these tend to be most noticeable during the initial weeks of treatment or shortly after a dose increase, typically easing as the body adjusts
